• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Potential antitumour activity of pasireotide on pituitary tumours in acromegaly.

作者信息

Coopmans Eva C, van der Lely Aart J, Schneiders Joppe J, Neggers Sebastian J C M M

机构信息

Pituitary Center Rotterdam, Endocrinology Section, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, 3015 GD, Netherlands.

Pituitary Center Rotterdam, Endocrinology Section, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, 3015 GD, Netherlands.

出版信息

Lancet Diabetes Endocrinol. 2019 Jun;7(6):425-426. doi: 10.1016/S2213-8587(19)30113-5. Epub 2019 Apr 4.

DOI:10.1016/S2213-8587(19)30113-5
PMID:30956093
Abstract
摘要

相似文献

1
Potential antitumour activity of pasireotide on pituitary tumours in acromegaly.帕瑞肽对肢端肥大症垂体肿瘤的潜在抗肿瘤活性。
Lancet Diabetes Endocrinol. 2019 Jun;7(6):425-426. doi: 10.1016/S2213-8587(19)30113-5. Epub 2019 Apr 4.
2
T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.T2 信号强度、SSTR 表达和生长抑素类似物的疗效可预测肢端肥大症患者对帕瑞肽的反应。
Eur J Endocrinol. 2020 Jun;182(6):595-605. doi: 10.1530/EJE-19-0840.
3
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.培高利特与奥曲肽治疗肢端肥大症的头对头优效性研究。
J Clin Endocrinol Metab. 2014 Mar;99(3):791-9. doi: 10.1210/jc.2013-2480. Epub 2014 Jan 13.
4
Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.长效帕瑞肽治疗生长抑素受体不敏感型肢端肥大症的疗效和安全性：一项多中心研究。
Endocrine. 2018 Nov;62(2):448-455. doi: 10.1007/s12020-018-1690-5. Epub 2018 Jul 26.
5
[Difficulties of treating acromegaly in the light of 12 years of experience].[基于12年经验谈肢端肥大症的治疗难点]
Orv Hetil. 2024 Oct 6;165(40):1587-1593. doi: 10.1556/650.2024.33156.
6
Comment on "Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal".关于“生长激素分泌型垂体腺瘤患者肢端肥大症的持续缓解：长效帕瑞肽治疗效果及停药后果”的评论
J Clin Pharm Ther. 2022 Sep;47(9):1490. doi: 10.1111/jcpt.13651. Epub 2022 Mar 21.
7
Radiotherapy and pasireotide treatment of a growth hormone producing pituitary tumor in a diabetic dog.一只患有糖尿病的犬垂体生长激素瘤的放射治疗和帕西瑞肽治疗
Can Vet J. 2018 Oct;59(10):1089-1093.
8
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.肢端肥大症患者皮下注射培高利特的长期疗效和安全性：一项开放性、多中心、II 期扩展研究的结果。
Pituitary. 2014 Apr;17(2):132-40. doi: 10.1007/s11102-013-0478-0.
9
Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.生长抑素类似物在肢端肥大症和胃肠胰神经内分泌肿瘤中的应用：过去、现在与未来
Endocr Relat Cancer. 2016 Dec;23(12):R551-R566. doi: 10.1530/ERC-16-0151. Epub 2016 Oct 3.
10
MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly.肢端肥大症患者使用生长抑素类似物治疗后生长激素腺瘤的MRI T2特征
Endocrine. 2016 Jul;53(1):327-30. doi: 10.1007/s12020-015-0816-2. Epub 2015 Nov 28.

引用本文的文献

1
Long-term Remission in Functioning Pituitary Adenomas after Medical Therapy Withdrawal: A Chance for Cushing's Disease.药物治疗停药后功能性垂体腺瘤的长期缓解：库欣病的一个机会。
Endocr Metab Immune Disord Drug Targets. 2025;25(10):824-833. doi: 10.2174/0118715303328077240719055819.
2
Case report: Management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism.病例报告：X 连锁肢端巨大症导致的儿童巨人症的治疗。
Front Endocrinol (Lausanne). 2024 Feb 28;15:1345363. doi: 10.3389/fendo.2024.1345363. eCollection 2024.
3
Efficacious Primary Pasireotide Therapy in a Case of a Large Invasive Adrenocorticotropin-secreting Pituitary Tumor.
帕西瑞肽一线治疗一例大型侵袭性促肾上腺皮质激素分泌型垂体瘤疗效显著
JCEM Case Rep. 2023 Dec 7;1(6):luad141. doi: 10.1210/jcemcr/luad141. eCollection 2023 Nov.
4
Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly.肢端肥大症患者帕西瑞肽剂量减少的长期真实世界经验。
Endocr Connect. 2023 Aug 1;12(10). doi: 10.1530/EC-23-0155.
5
Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience.生长激素腺瘤患者帕瑞肽治疗的长期疗效和安全性：单中心真实世界 14 年经验。
J Clin Endocrinol Metab. 2023 Nov 17;108(12):e1571-e1579. doi: 10.1210/clinem/dgad378.
6
Pleiomorphism plurihormonal Pit-1-positive macroadenoma with central hyperthyroidism: a rare case report and literature review.Pit-1 阳性多激素分泌垂体大腺瘤伴中枢性甲亢：罕见病例报告及文献复习。
BMC Endocr Disord. 2022 Dec 21;22(1):325. doi: 10.1186/s12902-022-01220-2.
7
Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR.在接受帕西瑞肽长效注射剂治疗的肢端肥大症患者中，胰岛素分泌受损而胰岛素抵抗无变化可解释高血糖现象。
Endocr Connect. 2022 Nov 17;11(12). doi: 10.1530/EC-22-0296. Print 2022 Dec 1.
8
Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.预测肢端肥大症治疗结果的生长激素垂体神经内分泌肿瘤的临床、激素和病理形态学标志物。
Front Endocrinol (Lausanne). 2022 Sep 16;13:957301. doi: 10.3389/fendo.2022.957301. eCollection 2022.
9
Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis.生长抑素类似物帕瑞肽治疗生长激素和促肾上腺皮质激素分泌型垂体腺瘤的疗效：系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2022 Jul 1;13:935759. doi: 10.3389/fendo.2022.935759. eCollection 2022.
10
Pasireotide-a novel somatostatin receptor ligand after 20 years of use.培高利特：20 年临床应用后新型生长抑素受体配体。
Rev Endocr Metab Disord. 2022 Jun;23(3):601-620. doi: 10.1007/s11154-022-09710-3. Epub 2022 Jan 24.